Clinical Report: Post-Prostate Biopsy Infection Risks and Antimicrobial Management 2010-2019

Overview

This global study analyzed infective complications following prostate biopsy (P-Bx) from 2010 to 2019, revealing symptomatic infection rates and trends over time. It highlighted the impact of antimicrobial resistance on prophylaxis failure and emphasized the importance of antimicrobial stewardship in managing post-biopsy infections.

Background

Prostate biopsy is a frequently performed urological procedure with over one million cases annually in the US. Since the adoption of transrectal biopsy techniques, symptomatic infectious complication rates have ranged widely and appear to be increasing. Risk factors such as older age and comorbidities have been implicated, but remain incompletely understood. Antimicrobial resistance among uropathogens has contributed to prophylaxis failure, underscoring the need for site-specific stewardship programs.

Data Highlights

Key Findings

• Symptomatic infectious complications after P-Bx ranged from 1.9% to 27.7%, with an increasing trend over time.
• Older age and comorbidities were associated with higher rates of infective complications post-biopsy.
• Antimicrobial resistance among uropathogens contributed to failure of antibiotic prophylaxis.
• 5.2% of men experienced symptomatic urinary tract infection and 3.5% had febrile infections in early study years (2010–2011).
• Hospital readmission due to infectious complications occurred in 3.1% of cases post-P-Bx.
• Antimicrobial stewardship and site-specific protocols are critical to managing infection risks effectively.

Clinical Implications

Clinicians should be vigilant for infective complications following prostate biopsy, especially in older patients and those with comorbidities. Given rising antimicrobial resistance, tailored antibiotic prophylaxis guided by local resistance patterns and stewardship programs is essential to reduce infection rates and hospital readmissions. Monitoring and early intervention for symptoms of UTI post-biopsy can improve patient outcomes.

Conclusion

This large-scale global study underscores the persistent risk of infectious complications after prostate biopsy and the growing challenge of antimicrobial resistance. Effective antimicrobial stewardship and individualized prophylactic strategies are vital to optimizing patient safety in this common urological procedure.

References

1. Borghesi et al. 2017 -- Infective complications after prostate biopsy
2. Global Prevalence Study of Infections in Urology (GPIU) 2003–2019 -- Antimicrobial resistance and infection rates
3. European Association of Urology (EAU) Guidelines 2020 -- Management of Infectious Complications